“And then we're also going to start our IDE trial for our trans-mitral valve replacement program too, which I think is going to be best-in-class.”

In context

“maging interventional cardiology company that's we're integrating that into our product offerings now for pre-procedure planning. So I think that's going to help also since imaging is such an important part in these procedures. And then the pipeline looks really good too. We've got our next-generation amulet. Expect to be launching that beginning of next year. We're going to go into trial, into our IDE trial with our balloon TAVR in the second half of this year. So, again, as I'm thinking about I know what's going to launch in 2027, and I know the impact that those launches are going to have in terms of our growth rate, and we're building our pipeline to be able to ensure that we can sustain that growth in 2028. And I look at this Balloon TAVR program as really being important to do that. And then we're also going to start our IDE trial for our trans-mitral valve replacement program too, which I think is going to be best-in-class. So I think this team has got not only an incredible pipeline to work with, but we've also been making the investments on the clinical side, clinical teams, sales reps, across the world. So I think we're well-positioned in our structural heart business. Crystal, we'll take one more question, please. Operator: Thank you. And our last question will come from Josh Jennings from TD Cowen. Your line is open. Josh Jennings: Just keep it to one on capital allocation, starting to circle back. But I think the focus for your team, Robert, has been to kind of look at inorganic ads for the devices and diagnostics franchise that played out with the Exact Sciences acquisition. I mean, should we be thinking that that remains the focus? Or is the nutrition recovery can you can that business get back to mi”